Since the crucial role of Rearranged During Transfection (RET) mutations in an relevant percentage of MTC cases (4), and the off-target toxicities often given by MKIs, two selective RET inhibitors, selpercatinib and pralsetinib have been evaluated and approved for patients with advanced or metastatic RET-mutant MTC, either somatic or germinal, and are currently the first lines of treatment for metastatic or progressive tumours presenting RET mutations (7–9). Here, RET is linked to neoplasm.